Milestone Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Hello, everyone, and good afternoon and welcome back to the H.C. Wainwright 24th Annual Global Investment hybrid conference. My name is Patrick Trucchio. I'm a Senior Healthcare Analyst at H.C. Wainwright. It's my pleasure to introduce our next presenter, Joseph Oliveto, CEO of Milestone Pharmaceuticals, a biopharmaceutical company focused on development of innovative cardiovascular treatments. With that, I hand over to Joseph.
Thank you so much, Patrick. I want to thank all the colleagues at H.C. Wainwright for inviting us today. And of course, thank you in the room and those listening online to the Milestone story. We will be making forward-looking statements. So, I'll direct you to our SEC filings for a full listing by risk factors.
So, just by way of overview, as Patrick had mentioned, Milestone is a Phase 3 cardiovascular company. We're focused on two particular types of tech, [cardial] SVTs for both of them. PSVT is our lead program, and we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |